Author(s):
Aiswarya Mohan, Aravind H, Chakravarthy S Maddipati, Roshni P R
Email(s):
chakravarthy@aims.amrita.edu , sirichakri@gmail.com
DOI:
10.52711/0974-360X.2021.00957 
Address:
Aiswarya Mohan1, Aravind H1, Chakravarthy S Maddipati2*, Roshni P R3**
1Doctor of Pharmacy (PharmD) Intern, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India.
2MD FACP, Consultant, Department of Internal Medicine, Amrita Institute of Medical Sciences, Kochi, 682041, Kerala, India.
3Assistant Professor, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 10,
Year - 2021
ABSTRACT:
Antithyroid drugs (ATD’s) are widely used as the first line treatment option for the management of hyperthyroidism, especially for patients with Graves’ disease. They are classified into thionamide (Methimazole, Carbimazole and Propylthiouracil) and Non-thionamide (Iodine containing compounds) ATD’s. These drugs are associated with various types of adverse effects ranging from mild to potentially life threatening. Antithyroid arthritis syndome (AAS) is one of the major and uncommon side effects of ATD therapy requiring immediate drug discontinuation and hospitalization presents itself with myalgia, arthralgia and arthritis along with fever and rash of varying severity and non-specific laboratory findings, making its diagnosis and management clinically challenging. Here we report the case of 32 year old female with Graves’ disease who experienced severe migratory polyarthritis after the initiation of methimazole therapy. Her symptoms started to disappear after the prompt withdrawal of methimazole. We also concluded that this adverse effect of ATD’s might not be dose dependent by comparing our case with 6 other case reports of AAS. Here our objective is to raise awareness among the clinicians regarding the differential diagnosis and management of this major, uncommon and potentially life threatening adverse effect of ATD therapy.
Cite this article:
Aiswarya Mohan, Aravind H, Chakravarthy S Maddipati, Roshni P R. A Case Report on Methimazole Induced Anti-Thyroid Arthritis Syndrome: A Rare Drug Induced Migratory Polyarthritis. Research Journal of Pharmacy and Technology 2021; 14(10):5483-8. doi: 10.52711/0974-360X.2021.00957
Cite(Electronic):
Aiswarya Mohan, Aravind H, Chakravarthy S Maddipati, Roshni P R. A Case Report on Methimazole Induced Anti-Thyroid Arthritis Syndrome: A Rare Drug Induced Migratory Polyarthritis. Research Journal of Pharmacy and Technology 2021; 14(10):5483-8. doi: 10.52711/0974-360X.2021.00957 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-10-75
REFERENCES:
1 Smith TJ. Hegedüs L. Graves' disease. New England Journal of Medicine. 2016 Oct 20; 375: 1552-65.
2. Suwansaksri et al. Nonthionamide drugs for the treatment of hyperthyroidism: From present to future. International Journal of Endocrinology. 2018 Jan 1; 2018.
3. Eliasson ME. M. Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000–2010. European Journal of Endocrinology. 2014; 170: 419-27.
4. Cooper DS. Antithyroid drugs. New England Journal of Medicine. 2005 Mar 3; 352: 905-17.
5. Jastrzębska H. Antithyroid drugs. InThyroid research 2015 Dec 1 (Vol. 8, No. S1, p. A12). Bio Med Central.
6. Liu et al. Antithyroid drug therapy for Graves’ disease and implications for recurrence. International Journal of Endocrinology. 2017 Apr 25; 2017.
7. Shabtai et al. The antithyroid arthritis syndrome reviewed. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1984 Feb;27: 227-9.
8. Mancuso et al. Colchicine as a new therapeutic option for antithyroid arthritis syndrome. Rheumatology. 2020 Jun 1; 59: 1452-3.
9. Khaledi et al. Arthritis Associated With Low Dose Methimazole Therapy: A Case Report. Iranian Journal of Pharmaceutical Sciences. 2018 Dec; 14: 55-62.
10. Modi et al. Antithyroid arthritis syndrome. Case Reports. 2017 Feb 27;2017:bcr2016218459.
11. Shikha et al. Antineutrophilic cytoplasmic antibody positive vasculitis associated with methimazole use. Case Reports in Endocrinology. 2015 Apr 28; 2015.
12. Pearce EN. Diagnosis and management of thyrotoxicosis. Bmj. 2006 Jun 8; 332: 1369.
13. Cooper DS. The side effects of antithyroid drugs. The Endocrinologist. 1999 Nov 1; 9: 457-78.
14. Ahamed et al. Insulin autoimmune syndrome (Hirata disease) associated with carbimazole therapy. Thyroid Research and Practice. 2010 Jan 1; 7: 22
15. Williams et al. Thiouracil Treatment of Thyrotoxicosis: II. Toxic Reactions. The Journal of Clinical Endocrinology. 1946 Jan 1; 6: 23-51
16. Ploegstra et al. Arthritis associated with antithyroid therapy in a 15-year-old girl. The Journal of Pediatric Pharmacology and Therapeutics. 2011; 16: 98-101.
17. Nikitopoulou E, Gazi S. Antithyroid drug induced syndrome that lies in between ANCA vasculitis and lupus like syndrome in a 40-year-old female with Graves’ disease under methimazole therapy: A Case report. Mediterranean Journal of Rheumatology. 2018; 29.
18. Karch FE, Lasagna L. Adverse drug reactions: a critical review. Jama. 1975 Dec 22;234: 1236-41.
19. Nihei et al. Polyarthritis caused by methimazole in two Japanese patients with Graves’ disease. Journal of Clinical Research in Pediatric Endocrinology. 2013 Dec;5: 270.
20. Takaya et al. Antithyroid arthritis syndrome: A case report and review of the literature. Internal Medicine. 2016 Dec 15; 55: 3627-33.
21. Cooper DS. Antithyroid drugs in the management of patients with Graves’ disease: an evidence-based approach to therapeutic controversies. The Journal of Clinical Endocrinology & Metabolism. 2003 Aug 1; 88: 3474-81.
22. Nakamura et al. Working Group of the Japan Thyroid Association for the Guideline of the Treatment of Graves’ Disease. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. The Journal of Clinical Endocrinology and Metabolism. 2007 Jun 1; 92: 2157-62.
23. Schatz SN, Weber RJ. Adverse drug reactions. ACCP (American College of Clinical Pharmacy). CNS. Pharmacy Practice, PSAP. 2015.
24. Naranjo et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981 Aug; 30: 239-45